In depth
IgG4-related disease: common questions
A review read 167 papers on this disease and found one of them that could serve as a care guideline. No other number describes the state of this field so well. What follows is built on that one document, and on the list of things this field still doesn't have.
What the research found.
A review read 167 papers on IgG4-related disease and found just one that could serve as a care guideline. That one is a consensus statement written across several specialties. It's the only document of its kind anywhere in this field, and that's the single most useful fact here.
That review listed four things this illness still lacks. There are no shared rules for sorting cases, no formal rules for the diagnosis, and no treatment advice backed by good trials. There's also no score for how active the illness is or how much harm it has done.
One trial gave 194 people either a drug called obexelimab or a dummy shot, weekly for a year, and the assignment was kept hidden from everybody involved. Flares hit 26 of the 97 on the drug, at 26.8 percent, against 53 of 97 on the dummy shot, at 54.6 percent. The hazard ratio was 0.44, with the true value somewhere from 0.28 to 0.71.
Della-Torre and colleagues, New England Journal of Medicine, 2026
One study asked 95 patients about their work and their exposures. Smoking was associated with more lung involvement, at an odds ratio of 3.2, where the true value is somewhere from 1.1 to 9.4. Cooking or heating with wood or coal was associated with a different form of the disease, at 2.6, from 1.03 to 6.9.
Martin-Nares and colleagues, Clinical and Experimental Rheumatology, 2024
One usable document out of 167
A European reference network read 167 papers on IgG4-related disease, looking for anything that could serve as a care guideline, and it found one. That one is a consensus statement, written by experts working across several different specialties. It's the only document of its kind in the whole field.
Then it listed what is missing from the field. There are no shared rules for sorting cases, no formal rules for making the diagnosis, and no treatment advice backed by good trials. There's also no score for how active the illness is or how much harm it has done.
That list is the most useful thing to know before you read anything else about this illness. Without shared rules there's no settled definition to measure you against, and without a score there's no agreed way to say whether your disease is getting better or worse. Doctors handle both of those with judgment, and knowing that changes what to expect from a visit.
Why this disease is hard to study
Three things make this disease hard to study properly. Doctors only recognized it as one illness fairly recently, so the research behind it is young. It turns up in many different specialties depending on which organ is hit, which scatters the expertise, and it's uncommon, which makes gathering enough patients slow.
Put those three together and you get the position the review describes. It isn't that the problem is being ignored. It's that one illness walks into a gut clinic, an eye clinic, a kidney clinic, and a rheumatology clinic, and in each of those it can look like a different problem entirely.
For a patient, the practical result of all that is worth spelling out. Different specialists may describe one disease in different terms, and whoever coordinates your care counts for more here than in an illness with a settled definition. That's a reason to ask who is doing the coordinating.
Why which organ is involved changes everything
This illness settles in many different places in the body. It can hit the spit glands, the eye socket, the pancreas, the kidneys, or the tissue at the back of the belly, and two people with one diagnosis between them can be in genuinely different situations. That counts for more here than in almost any other illness on this site.
Advice written with one organ in mind can be useless or plain wrong for another. So the first thing to settle is which organ is involved in your own case, and the second is what that means for what you should be watching for. Both of those are questions for your team rather than for a page.
Ask them straight out, because it's a fair question and it changes what any general advice is worth to you. Without that answer, a watch-list written for this illness isn't really a watch-list for you at all. It's a list for a category you happen to be in.
What is thin here, and what no longer is
The evidence base in this disease is thin, and it's a good deal less thin than it was a year ago. Two things this page used to say were missing are now covered by something. It's worth saying which of them, because the change is recent.
The blood test has two reviews behind it now. One pooled 23 studies and 6048 patients, and found it catching 85 percent of cases and clearing 93 percent of people without the disease. The other pooled 9 studies and found 87.2 percent and 82.6 percent at the lower cut-off, and the labs page here sets both of them out in full.
Treatment has one trial behind it as well. It gave 194 people either obexelimab or a dummy shot for a year, and flares hit 26.8 percent on the drug against 54.6 percent on the dummy shot. The hazard ratio was 0.44, ranging from 0.28 to 0.71.
What's still missing is the framework around all of that. The unmet-needs list says there are no treatment recommendations backed by evidence, and one trial doesn't change that on its own. It does mean the field now has something to build a recommendation on, which it didn't have before.
Diet and exercise remain untested in this disease, and no trial of either has been run. There's a reason for that beyond neglect, because without an agreed score for disease activity a diet study would have nothing to measure against. The missing treatment research comes on top of missing measurement.
What is reasonable to do
Stay active for the reasons everybody has, and put in weight-bearing and strength work if you're on a long corticosteroid course, because a guideline asks for those two things by name. Neither of those comes from research in this illness. The second of them follows from your treatment rather than from your diagnosis.
Ask for measurement before supplements, because that order counts for more here than it usually does. This illness can affect organs that change how you handle nutrients, and which organ is involved decides whether that applies to you. Take something without measuring and you can spend years on it for no reason at all.
Bring the specifics of your own organ involvement to your visits, not the general picture. This disease looks completely different depending on where it settles, and five things are worth mentioning. Those are weight loss, any change in your stools, getting thirstier or going to the toilet more, yellow eyes or skin, and swelling anywhere.
Common misconceptions.
Myth. There's an established set of criteria for diagnosing this.
Reality. There isn't one, and the review of this field listed the missing rules for sorting cases as one of its unmet needs. Three more came with it, which are no formal rules for the diagnosis, no treatment advice backed by good trials, and no score for how active the illness is. That review read 167 papers and found one that could serve as a care guideline.
Myth. There's a diet that treats this illness.
Reality. No trial of any diet has been run in IgG4-related disease, and there's a deeper reason for that than neglect. The review of this field found no agreed score for how active the illness is, so a diet study would have nothing to measure against. Anything sold to you as a diet for this illness has cleared no bar at all.
Myth. A raised IgG4 level makes the diagnosis.
Reality. It doesn't make the diagnosis, and two reviews put numbers on why. One pooled 23 studies and 6048 patients, where the test caught 85 percent of cases and cleared 93 percent of people without the disease. The other pooled 9 studies and found 87.2 percent and 82.6 percent at the lower cut-off, so some people without this disease test positive.
Myth. Nothing can be done because the research is thin.
Reality. Some things can be done, and what's thin is the research on sorting cases, measuring the illness, and testing treatments. Your treatment is a different matter, because most people here take corticosteroids for a stretch and a guideline covers that in detail. It asks for calcium and vitamin D, for weight-bearing and strength work, for stopping smoking, and for cutting back on alcohol, and that has a document behind it.
Questions patients ask.
How much is known about this disease?
Less is known here than about almost any illness on this site. A review read 167 papers and found one that could serve as a care guideline, and that one is a consensus statement written by experts across several specialties. The review then listed four things missing, which are shared rules for sorting cases, formal rules for the diagnosis, treatment advice backed by good trials, and any score for how active the illness is.
Why does that matter to me?
Because it explains two things you may well run into. Different specialists may describe your disease differently, and what you get told about it can change over time. Without shared rules or a score there's no agreed way to say how active the illness is, or to compare you against anybody else, so doctors handle that with judgment.
Is there a diet for IgG4-related disease?
No, because no trial of any diet exists in this illness, and the reason runs deeper than neglect. The review of this field found no agreed score for how active the disease is, so a diet study would have nothing to measure against. Anything sold to you as a diet for this illness has cleared no bar, because there's no bar here yet.
What should I be watching for?
That depends on which organ is affected, and it counts for more here than in most illnesses. This disease looks completely different depending on where it settles, so the honest answer is to settle that question with your team first. Then ask what to mention, given where your disease sits, because general watch-lists for this illness are less use than they look.
Should I be taking vitamin supplements?
Get your levels measured before you add anything, because that order counts for more here than usual. This illness can affect organs that change how you handle nutrients, and whether that applies to you depends on which organ is involved. So it's a question for the team looking after you rather than a general rule anybody can print.
Is there exercise research in this condition?
Not a single one, because nothing published here has tested exercise or activity. So any advice you're given for this diagnosis is borrowed from somewhere else, and usually the borrowing goes unmentioned. The plain case for staying active still holds, and if you're on a long corticosteroid course, a guideline asks for weight-bearing and strength work in those words.
Has anything been tested in a proper trial?
Yes, and that trial evidence is new here. One trial gave 194 people either obexelimab or a dummy shot, weekly for a year, and the assignment was kept hidden from everybody involved. Flares hit 26.8 percent on the drug and 54.6 percent on the dummy, full remission at a year ran 37.1 percent against 19.6, and people on the drug took far less corticosteroid. The drug company paid for the trial itself.
Does anything in my surroundings play a part?
There's a signal here and it isn't settled. One study asked 95 patients about work and exposures, where smoking was associated with more lung involvement at an odds ratio of 3.2, ranging from 1.1 to 9.4. Cooking or heating with wood or coal was associated with a different form of the disease, at 2.6 from 1.03 to 6.9, and that study looked at one moment in time.
Why is the research so thin?
Three reasons, and the first is that doctors only saw it as one illness fairly recently. It turns up in many fields of medicine depending on which organ is hit, and it isn't common, so a joined-up research effort is hard to build. The review that made the unmet-needs list exists because somebody spotted the problem rather than because anybody fixed it.
What should I take to my next appointment?
Which organ is causing your symptoms, and what has changed about it lately. This disease looks completely different depending on where it settles, and five things are worth mentioning: weight loss, any change in your stools, getting thirstier or going to the toilet more, yellow eyes or skin, and swelling anywhere. If you've been on corticosteroids a while, ask about a bone density scan too.
References.
- Iaccarino L; Talarico R; Scirè C et al. IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open. 2019;4:e000787. 10.1136/rmdopen-2018-000787Systematic literature review for clinical practice guidelines in IgG4-related disease
- Della-Torre E; Baker MC; Zhang W et al. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med. 2026. 10.1056/NEJMoa2601337Phase 3
- Martín-Nares E; Gamboa-Espíndola M; Hernández-Molina G. Occupational, smoking and biomass fuel exposure in a cohort of Mexican patients with IgG4-related disease. Clin Exp Rheumatol. 2024;42:2357-2361. 10.55563/clinexprheumatol/163s3tCross-sectional study of 95 Mexican patients with IgG4-related disease
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.